mdlinx mdlinx
Latest (24) Full Text Articles (547) Article Summary

Cytokinetics announces ck-2017357 receives fast track designation from the fda for the potential treatment of amyotrophic lateral sclerosis Full Text
Cytokinetics,

Cytokinetics, Incorporated announced that CK–2017357, its fast skeletal muscle troponin activator, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig's Disease. CK–2017357, the lead drug candidate from the company's skeletal sarcomere activator program, is currently in Phase II clinical trials intended to inform a potential registration program. Cytokinetics anticipates that results from two recently completed Phase II clinical trials, designed to assess the safety and tolerability of CK–2017357 in patients with ALS, will be presented at the American Academy of Neurology 64th Annual Meeting in New Orleans, LA on April 2012.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Pharma News

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharma News Articles

Last month's top read Top Articles of 2013

Indexed Journals in Pharma News: U.S.Pharmacist, FDA Drug Alerts, Pharmiwebmore

Other Topics in Pharma News

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register
Upcoming Clinical Trials UPCOMING Clinical Trials

Stay current - Media Tool

Newsletter
RSS
Follow
Like

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close